Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S-ribosylhomocysteine lyase (LuxS) is an iron-dependent metalloenzyme (EC 4.4.1.21) found in many bacteria that cleaves S-ribosylhomocysteine to produce L-homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), the precursor of the universal bacterial signaling molecule autoinducer-2 (AI-2)[1][2][4][7]. LuxS plays a key role in bacterial quorum sensing, a system of cell communication based on cell density that regulates biofilm formation, virulence, antibiotic resistance, and other group behaviors. It is highly conserved and encoded by the luxS gene in most bacteria[1][2][7]. LuxS belongs to the carbon-sulfur lyase class and requires a metal cofactor, commonly Fe2+, for its catalytic activity[1][3][5][10]. The enzyme is of significant interest as a potential antibacterial drug target due to its central role in regulating multicellular behaviors in pathogenic bacteria[3][5][7].
Inhibition of quorum sensing, Disruption of AI-2 signaling pathway, Interference with bacterial communication and virulence
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-ribosylhomocysteine lyase (LuxS).